← Eichor
Condition: Dlbcl Nos Genetic Subtypes Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Dlbcl Nos Genetic Subtypes

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or
EARLY_Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT04512716Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relap
Phase 2 · 1 location(s) · Australasian Leukaemia and Lymphoma Group · NCT06287398Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma
Phase 1 · 1 location(s) · Shanghai Exuma Biotechnology Ltd. · NCT06830031
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.